CoChat

Dulaglutide Protects Mice against Diabetic Sarcopenia-Mediated Muscle Injury by Inhibiting Inflammation and Regulating the Differentiation of Myoblasts

Open access
Deng, Fengyi, Wu, Wenyan, Fan, Xingyu, Zhong, Xing, Wang, Nuojin, Wang, Yue, Pan, Tianrong, Du, Yijun · 2023 · International Journal of Endocrinology

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Background. Type 2 diabetes mellitus increases the risk of sarcopenia, which is characterized by decreased muscle mass, strength, and function. However, there are no effective drugs to treat diabetic sarcopenia, and its underlying mechanism remains unknown. Here, we aimed to determine whether the GLP-1 receptor agonist (GLP-1RA) dulaglutide (Dul) affects the progression of diabetic sarcopenia. Methods. db/db mice were injected intraperitoneally with 0.6 mg/kg dulaglutide for 10 weeks. Mouse muscle tissues were then pathologically evaluated and stained with F4/80 or MPO to detect macrophages and neutrophils, respectively. In addition, inflammatory factors and FNDC5 in the muscle tissues were detected using qRT-PCR. Moreover, C2C12 cells were induced to enable their differentiation into skeletal muscle cells, and muscle factor levels were then detected. Furthermore, changes in muscle factor levels were detected at various glucose concentrations (11 mM, 22 mM, and 44 mM). Results. In vivo, dulaglutide alleviated muscle tissue injury; reduced levels of the inflammatory factors, IL-1β, IL-6, CCL2, and CXCL1; and reversed the level of FNDC5 in the muscle tissues of db/db mice. In vitro, a C2C12 cell differentiation model was established through the observation of cell morphology and determination of myokine levels. Upon stimulation with high glucose, the differentiation of C2C12 cells was inhibited. Dulaglutide improved this inhibitory state by upregulating the levels of both FNDC5 mRNA and protein. Conclusions. Treatment with the GLP-1RA dulaglutide protects db/db mice against skeletal muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts. High glucose inhibited the differentiation of C2C12 cells and decreased the mRNA and protein levels of myokines. Dulaglutide could reverse the differentiation state induced in C2C12 cells by high glucose.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2023/9926462

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Dulaglutide treatment inhibited diabetes‐induced muscle atrophy. (a) Histopathological image of HE-stained muscles (scale bars: 100 μm and 50 μm). (b) Statistical analysis of the mean cross-sectional area of soleus muscles. (c) RNA was extracted from the soleus muscles, and the mRNA levels of FNDC5 were detected. ∗∗∗P < 0.001, ∗comparison between the db/db group and control db/m group; #P < 0.05, ##P < 0.01, #comparison between the dulaglutide-treated group and db/db group.
Figure 1 Dulaglutide treatment inhibited diabetes‐induced muscle atrophy. (a) Histopathological image of HE-stained muscles (scale bars: 100 μm and 50 μm). (b) Statistical analysis of the mean cross-sectional area of soleus muscles. (c) RNA was extracted from the soleus muscles, and the mRNA levels of FNDC5 were detected. ∗∗∗P < 0.001, ∗comparison between the db/db group and control db/m group; #P < 0.05, ##P < 0.01, #comparison between the dulaglutide-treated group and db/db group.CC BY · PubMed Central
Figure 2 Dulaglutide inhibited the inflammatory response in mice with diabetes‐induced muscle atrophy. (a-b) The mRNA levels of IL-1β, IL-6, TNF-α, CCL2, CXCL1, and CXCL2 in soleus muscles were measured using qRT-PCR. ∗P < 0.05, ∗comparison between the db/db group and control db/m group; #P < 0.05, ###P < 0.001, #comparison between the dulaglutide-treated group and db/db group.
Figure 2 Dulaglutide inhibited the inflammatory response in mice with diabetes‐induced muscle atrophy. (a-b) The mRNA levels of IL-1β, IL-6, TNF-α, CCL2, CXCL1, and CXCL2 in soleus muscles were measured using qRT-PCR. ∗P < 0.05, ∗comparison between the db/db group and control db/m group; #P < 0.05, ###P < 0.001, #comparison between the dulaglutide-treated group and db/db group.CC BY · PubMed Central
Figure 3 Dulaglutide attenuated inflammatory cell infiltration in diabetes‐induced muscle atrophy. (a, b) The macrophage marker F4/80 and neutrophil marker MPO in the soleus muscles of mice were stained and their expression levels were analyzed using immunohistochemistry. The scale bars represent 100 μm and 50 μm, respectively. ∗∗∗P < 0.001, ∗comparison between the db/db group and control db/m group; ##P < 0.05, #comparison between the dulaglutide-treated group and db/db group.
Figure 3 Dulaglutide attenuated inflammatory cell infiltration in diabetes‐induced muscle atrophy. (a, b) The macrophage marker F4/80 and neutrophil marker MPO in the soleus muscles of mice were stained and their expression levels were analyzed using immunohistochemistry. The scale bars represent 100 μm and 50 μm, respectively. ∗∗∗P < 0.001, ∗comparison between the db/db group and control db/m group; ##P < 0.05, #comparison between the dulaglutide-treated group and db/db group.CC BY · PubMed Central
Figure 4 Effect of different glucose concentrations on the proliferation and differentiation of C2C12 cells. (a) C2C12 cells were plated in 96-well plates, and the SRB assay was used to detect the viability of C2C12 cells after administration of glucose at different concentrations. (b–d) C2C12 cells were treated with varying glucose concentrations, and the mRNA expression levels of the differentiation genes MyHC4 and MyHC7, the myogenic factor MyoD, and the muscle secretory factors FNDC5 and BDNF were detected. ∗∗∗P < 0.001, ∗comparison between the high glucose concentration group and the normal group.
Figure 4 Effect of different glucose concentrations on the proliferation and differentiation of C2C12 cells. (a) C2C12 cells were plated in 96-well plates, and the SRB assay was used to detect the viability of C2C12 cells after administration of glucose at different concentrations. (b–d) C2C12 cells were treated with varying glucose concentrations, and the mRNA expression levels of the differentiation genes MyHC4 and MyHC7, the myogenic factor MyoD, and the muscle secretory factors FNDC5 and BDNF were detected. ∗∗∗P < 0.001, ∗comparison between the high glucose concentration group and the normal group.CC BY · PubMed Central
Figure 5 Expression of myostatin, PGC-1α, and FNDC5 in C2C12 cells treated with different glucose concentrations. (a) C2C12 cells were induced to differentiate and then treated with different glucose concentrations for 24 h. The C2C12 protein was extracted, and the expression levels of myostatin, FNDC5, and PGC-1α proteins were detected. (b) The Image J software was used to analyze the gray value of proteins after the stimulation of C2C12 cells with high glucose concentrations, and statistical analysis was performed. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗comparison between the high glucose concentration group and the normal group.
Figure 5 Expression of myostatin, PGC-1α, and FNDC5 in C2C12 cells treated with different glucose concentrations. (a) C2C12 cells were induced to differentiate and then treated with different glucose concentrations for 24 h. The C2C12 protein was extracted, and the expression levels of myostatin, FNDC5, and PGC-1α proteins were detected. (b) The Image J software was used to analyze the gray value of proteins after the stimulation of C2C12 cells with high glucose concentrations, and statistical analysis was performed. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗comparison between the high glucose concentration group and the normal group.CC BY · PubMed Central
Figure 6 Effect of Dulaglutide on C2C12 cells treated with high glucose concentrations. (a) C2C12 cells were induced to differentiate and treated with 100 nM dulaglutide and 11 mM glucose for 24 h. RNA was extracted from these C2C12 cells, and the expression levels of MyHC4, MyHC4, and FNDC5 were detected. (b) Proteins were extracted from C2C12 cells, and the WB assay was performed for FNDC5. ∗P < 0.05, ∗comparison of CON between the glucose group and control group; #P < 0.05, ##P < 0.01, #comparison between the dulaglutide treated.
Figure 6 Effect of Dulaglutide on C2C12 cells treated with high glucose concentrations. (a) C2C12 cells were induced to differentiate and treated with 100 nM dulaglutide and 11 mM glucose for 24 h. RNA was extracted from these C2C12 cells, and the expression levels of MyHC4, MyHC4, and FNDC5 were detected. (b) Proteins were extracted from C2C12 cells, and the WB assay was performed for FNDC5. ∗P < 0.05, ∗comparison of CON between the glucose group and control group; #P < 0.05, ##P < 0.01, #comparison between the dulaglutide treated.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 26

Metadata

Authors
Deng, F., Wu, W., Fan, X., Zhong, X., Wang, N., Wang, Y., Pan, T., & Du, Y.
Affiliations
Second Affiliated Hospital of Anhui Medical University (CN)
Corresponding author
  • Wang, Yue
  • Pan, Tianrong
  • Du, Yijun
Venue
International Journal of Endocrinology
Publisher
Wiley
Published
2023-08-07
Volume
2023
Pages
1-10
ISSN
  • 1687-8337 (ISSN-L)
  • 1687-8345
OpenAlex
W4385623415
Cited by
26
References
33
Citations by year
2026: 6 · 2025: 10 · 2024: 7 · 2023: 3
FWCI
2.31
Type
journal article
Language
en
Open access
Locations
  • International Journal of Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (82200805, 2021lcxk024, 2022xkj033, MBLHJJ202002, MBLHJJ202005)
  • Anhui Medical University (82200805, 2021lcxk024, 2022xkj033, MBLHJJ202002, MBLHJJ202005)
  • Joint Research Fund for Chronic Disease Prevention and Control (82200805, 2021lcxk024, 2022xkj033, MBLHJJ202002, MBLHJJ202005)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
dulaglutide, GLP-1 receptor agonists, skeletal muscle injury, inflammation, myogenesis, FNDC5, myokines, high glucose, db/db mice, C2C12 myoblasts, interleukin-6, MCP-1, CXCL1, macrophages, neutrophils

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dulaglutide Protects Mice against Diabetic Sarcopenia-Mediated Muscle Injury by Inhibiting Inflammation and Regulating the Differentiation of Myoblasts. https://app.cochat.ai/papers/10.1155/2023/9926462
The paper
Deng, F., Wu, W., Fan, X., Zhong, X., Wang, N., Wang, Y., Pan, T., & Du, Y. (2023). Dulaglutide Protects Mice against Diabetic Sarcopenia-Mediated Muscle Injury by Inhibiting Inflammation and Regulating the Differentiation of Myoblasts. International Journal of Endocrinology. https://doi.org/10.1155/2023/9926462

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.